ClinicalTrials.gg
RecruitingNCT07318155Updated Apr 29, 2026

A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease

A Phase 2 interventional study of SRSD107 and 0.9 % sodium chloride in Coronary Artery Disease (CAD) and Peripheral Arterial Disease, sponsored by Sirius Therapeutics Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Sirius Therapeutics Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Mar 2025, registered Dec 2025).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.

Planned enrollment
248th of 324
104 · median 307
Started
2025
with 40 others
Phase 2
12 of 543
4 open now
Primary completion
2027-12
later than 135 of 209 live
Registered
471st of 543
by date

Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 248th largest by planned enrollment of the 324 interventional ones that give a count, is one of 41 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 135 of the 209 other live ones, and was the 471st registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:

171 more — sign in →

All 176 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 543 studies in Coronary Artery Disease with a site in China, or all of them as a file.
02

Study summary

The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.

03

Conditions studied

  • Coronary Artery Disease (CAD)
  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
  • Males or females aged 18 to 75 years, inclusive.
  • (BMI) between 18.0 and 35.0 kg/m2, inclusive.
  • History of chronic coronary and/or peripheral arterial disease

Exclusion criteria

Exclusion Criteria:

  • Known bleeding disorder
  • Severe heart failure with known \<35%, or (NYHA) class III or IV symptoms.
  • Genetic cardiomyopathies or other non-ischemic cardiomyopathies that are not related to atherosclerotic cardiovascular disease.
  • History of ethanol abuse or addictive drug use (cannabis products allowed) within 6 months of screening.
  • Receipt of an drug (IP) within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study.
  • Previous use of SRSD107.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    SRSD107 dose level 1

    Administered S.C.

    Drug: SRSD107

  • Experimental
    SRSD107 dose level 2

    Administered S.C.

    Drug: SRSD107

  • Experimental
    SRSD107 dose level 3

    Administered S.C.

    Drug: SRSD107

  • Experimental
    SRSD107 dose level 4

    Administered S.C.

    Drug: SRSD107

  • Placebo comparator
    Placebo

    Administered S.C.

    Drug: 0.9 % sodium chloride

Interventions

  • Administered S.C.

  • Drug0.9 % sodium chloride

    Administered S.C.

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in time-averaged FXI antigen

    Time frame: 72 weeks

Secondary outcomes

  1. Percent change from baseline in FXI antigen, FXI activity and aPTT

    Time frame: 72 weeks

  2. Maximal concentration of SRSD107

    Time frame: 72 weeks

  3. Area under the concentration-time curve from time 0 to infinity of SRSD107

    Time frame: 72 weeks

  4. Time to the maximal concentration of SRSD107

    Time frame: 72 weeks

  5. Incidence of adverse events

    Time frame: 72 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

Of 26 industry-sponsored phase 2 interventional studies under Coronary Artery Disease, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 29. This study's planned 33 months is above that.

Counting every sponsor, half of 55 studies reached it within 28 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2025
First posted
Jan 5, 2026
StartActual
Mar 11, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07318155
Lead sponsor
Sirius Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Mar 11, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Apr 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SRSD107

Start the discussion